ASTCT Supports the FDA's Approval of Earlier Use of CAR T-Cell Therapy for Multiple Myeloma tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
The Food and Drug Administration approves CAR T-Cell therapy Abecma as a second-line treatment and the CAR T-Cell therapy Carvykti as a third-line treatment for multiple myeloma.CHICAGO, IL / ACCESSWIRE / April 10, 2024 / The American Society for Transplantation and Cellular Therapy® (ASTCT®) supports the decision b.
Hana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.